CSIR-NCL has
developed a Novel catalytic &
highly selective process for the production of Imeglimin, a novel & safer metformin-substitute
for treatment of Type-2 diabetes. Imeglimin was launched in Japan in 2021 as an
anti-diabetic drug with significant advantages over metformin hydrochloride
which can cause hypoglycemia & vitamin B-12 deficiency with prolonged use. The
developed technology can be leveraged to produce Imeglimin with higher
selectivity while addressing issues such as solubility limitations, longer
reaction time, more downstreaming steps, water footprints, etc. The process is
optimized and scaled up to the batch size of 10 kg at TRL-4 and is currently available
for licensing/ co-development.
प्रौद्योगिकी प्रस्ताव
- Reusable Heterogeneous Catalyst
Batch Size: 10 kg
Reduced water footprint
Racemic Yield 85%
Efficient downstream protocol
Reusable Solvent
अनुप्रयोग
Treatment of Type-2 Diabetes
वर्तमान स्थिती
- TRL-4: Demonstrated at 10 kg Batch Size
- Available for Licensing/ co-development
मूल्य प्रस्ताव
- Inexpensive heterogeneous catalyst
- Scalable & Cost-effective Process
- Racemic Yield of up to 85%
- Significant reduction in wastewater Generation
- Improved solubility limitations
- Less Downstreaming steps
विशेषताएँ
- Reusable novel Heterogeneous Catalyst
- 100% Key Starting Material conversion
- Highly selective (97%) process
- High Racemic yields (up to 85%)
- Less effluent discharge
- Reduced reaction time
- Reusable solvent
अन्य सूचना
बाज़ार संभाव्यता
TWYMEEG® net sales in Japan has reached JPY 5 billion (USD 33 million) in 2024
- India has approved Imeglimin in January 2023
पृष्ठभूमि
- India's Type-2 diabetes cases may reach 134 million by 2045
- Prolonged use of Metformin can cause gastro intolerance & vit B-12 deficiency
- Imeglimin (TWYMEEG®), a novel & safer alternative, was launched in Japan.
- Our technology offering improves its synthesis & economics by addressing existing issues of solubility limitations, longer reaction time, more downstreaming steps, water footprints, etc.